Antisense Oligonucleotide Drug Class List

Drugs in Drug Class: Antisense Oligonucleotide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes	9,181,549			Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes	8,101,743		Y	Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes

Market Dynamics and Patent Landscape for Antisense Oligonucleotide Drugs: Exclusivity Timelines, Patent Estates, and Generic/Biosimilar Entry Risks

Last updated: June 29, 2026

Antisense oligonucleotide (ASO) drugs are protected by dense, layered IP across sequence, chemistry, delivery, target biology (method-of-use), and manufacturing. Market dynamics skew toward platform owners and sequence developers that control clinical-stage assets, vector- or conjugate-enabled sub-platforms, and late-life line extensions. Entry risk for “generic ASOs” is structurally higher than for small molecules because regulators treat ASOs as complex drug products where exact sequence and chemical identity matter.

---

What patents protect antisense oligonucleotide drugs (ASOs)?

Core ASO patent estates typically combine: (1) sequence claims over the therapeutic oligonucleotide, (2) chemical modification claims (backbone and nucleobase modifications), (3) formulation and delivery claims (conjugates, lipids, nanoparticles, conjugated ligands, salts), (4) method-of-use claims (target, patient population, dosing regimen), and (5) manufacturing process claims (solid-phase synthesis steps, purification specifications, impurity control, scale-up).

Which claim types dominate ASO patent portfolios?

1) Sequence and antisense activity claims

• Nucleotide sequence claims specifying the exact oligonucleotide.
• Variants claims: substitutions at defined positions, mismatch tolerability, length ranges, or “substantially identical” sequences.
• Binding claims: duplex formation, binding affinity windows, or inhibition metrics (often tied to in vitro potency).

2) Chemical structure and modification claims

• Phosphorothioate (PS) backbones and mixed-backbone variants.
• 2’-O-methoxyethyl (2’-MOE), 2’-fluoro (2’-F), 2’-ribose modifications.
• Locked nucleic acid (LNA) motifs, constrained geometries, or end-capping chemistries.
• “Chimeric” or “gapmer” configurations (where used).

3) Delivery, conjugation, and formulation claims

• Ligands (GalNAc, antibodies, peptides) and conjugate chemistry.
• Lipid nanoparticle approaches (when applicable).
• Salt forms and composition claims (buffers, excipients, concentration ranges).
• Sterile filtration and stability-related formulation claims.

4) Therapeutic use and regimen claims

• Target gene and pathway claims.
• Patient stratification: biomarker thresholds, genotype-defined populations.
• Dosing: loading doses, maintenance intervals, infusion volumes, injection-site parameters.
• Combination therapy claims (ASO plus another therapy, including biologics).

5) Manufacturing and control claims

• Synthesis route claims (protected phosphoramidites, coupling cycles).
• Purification and polishing: HPLC fractionation windows, ion exchange steps.
• Impurity control: residual solvents, deprotected nucleobases, truncated oligos.
• Stability and shelf-life methods: accelerated degradation test methods and acceptance criteria.

How many patents can cover one ASO product?

ASO portfolios can include dozens of active patent families, often spanning multiple jurisdictions. A typical profile in major ASO launches includes:

• 1 to 3 families on the active sequence and key modification pattern.
• 2 to 5 families on chemistry refinements and variants.
• 1 to 4 families on formulation/delivery (including salts, excipients, conjugation).
• 2 to 6 families on methods of use and regimens.
• Several families on manufacturing steps and impurity control.

The practical result is a “forest” effect: multiple overlapping expiration dates, with later-expiring line extension families and process patents extending enforcement leverage even as initial sequence claims age out.

---

When does exclusivity end for antisense oligonucleotide drugs?

ASO exclusivity typically stacks:

1. Hatch-Waxman patent protection for “new chemical entity” and composition-of-matter patents (when applicable),
2. marketing exclusivity (3-year new drug exclusivity; 5-year if new indication or orphan-related exclusivity requirements are met),
3. Pediatric exclusivity (up to 6 months),
4. Orphan Drug exclusivity (7 years) where applicable,
5. Potential data exclusivity layers based on regulatory history and approvals.

How do FDA marketing exclusivities stack for ASOs?

• 3-year NCE exclusivity attaches to the application with a new active ingredient and prevents generic approval submission for that NDA (and blocks ANDA approval timing under Hatch-Waxman).
• 5-year exclusivity applies when the sponsor proves substantial evidence of effectiveness for a new clinical investigation under specified frameworks and meets criteria tied to new indication.
• Orphan exclusivity can provide 7 years from NDA approval in the orphan-labeled indication, subject to orphan-specific triggers (loss of designation, subsequent approval for same drug in different indication under criteria, or sponsor failure to maintain orphan status).
• 6-month pediatric extension can extend patent expiry timing under certain conditions.

What is the effective “data-to-generic” window for ASOs?

Even when formal exclusivity ends, patent litigation and patent-specific expiry schedules often delay ANDA-like entry. For ASOs, the key constraint is not only regulatory exclusivity but IP breadth:

• If sequence-specific patents remain enforceable, a “close variant” can still infringe.
• If method-of-use patents remain enforceable, a carve-out through dosing/regimen or population selection may reduce risk but rarely avoids all infringement.
• Process/manufacturing patents can block manufacturing in the U.S. even if an applicant chooses a non-infringing sequence variant.

---

Which patents drive settlement leverage in ASO Paragraph IV cases?

Paragraph IV challenges in complex drug products often target specific, later-expiring patents. Settlement leverage typically reflects:

• Whether the applicant can design around sequence and chemistry without losing potency/safety.
• Whether there is a non-infringing manufacturing pathway.
• Whether the sponsor’s remaining patents include formulation/delivery and regimen claims enforceable in the launch indication.

Why design-arounds are harder for ASOs

For small molecules, generics can change structure while preserving function. For ASOs:

• The oligonucleotide sequence and chemical modifications define binding and activity.
• “Same target” does not guarantee “same drug” in infringement analysis.
• Even minor changes can shift potency, tissue distribution, and toxicology.

Common settlement structures for complex antisense drugs

Across complex oral and injectable drug products (and increasingly for oligonucleotide families), settlement terms often include:

• Timed launch dates (delayed “generic” entry).
• Carve-outs by indication or patient subset (less common in ASOs but possible).
• Patent-specific covenant-not-to-sue agreements.
• Technology transfer timelines for manufacturing.

Because ASOs are complex and typically delivered in controlled settings, sponsors often negotiate broader covenants that reduce launch risk for applicants.

---

What is the Orange Book status of antisense oligonucleotide drugs?

For most ASO NDAs, the Orange Book lists patents categorized as:

• Drug substance (composition-of-matter),
• Drug product (formulation/composition),
• Methods of use.

The Orange Book often shows multiple listed patents with different expiration dates, which materially affects ANDA timing. The controlling question in ASO launches is how many “active” Orange Book patents remain unexpired at the time of challenge and whether the applicant can avoid each.

How to read Orange Book coverage for ASOs

• Focus on the “earliest effective expiration” and the “last-to-expire” patents.
• Identify whether the later-expiring patents are sequence-related (rarely easy to design around), formulation/delivery related (often hard to replicate exactly), or regimen related (sometimes easier to avoid via labeling carve-outs).
• Watch for continuations that add new families with different effective filing dates, creating overlapping protection windows.

---

How strong is the patent estate for major antisense oligonucleotide targets?

ASO strength is typically high due to:

• Many independent claim families.
• Clear structural definition for infringement when sequence/chemistry claims are asserted.
• Product-specific formulation and manufacturing claims that limit non-infringing supply.

What makes ASO patent strength “high” in practice?

• The patent estate is often not a single “composition-of-matter” bottle-neck. It is a layered set of claims that map to distinct stages: target binding, chemical identity, formulation stability, delivery to relevant tissues, and manufacturing.
• Many claims are supported by extensive experimental data within specifications, enabling robust validity narratives.
• District courts have adjudicated complex nucleic-acid chemistries, increasing the likelihood that claim construction can preserve enforceability for structurally defined patents.

---

How does an antisense oligonucleotide compare with small-molecule generic entry risks?

Regulatory pathway differences

• Small molecules face ANDA-like pathways with generic bioequivalence.
• ASOs typically require more complex characterization, with regulators emphasizing identity (sequence), chemical composition, and functional equivalence, often using in vitro potency and pharmacodynamic markers tailored to the mechanism.

IP pathway differences

• Generics can alter structure and still meet functional equivalence for small molecules, then rely on narrower functional infringement.
• ASO infringement is strongly tied to sequence and structure. Even if pharmacodynamics align, structural similarity can drive infringement.

Commercial consequence

ASO generic entry risk is typically:

• Higher for early entry around sequence claims.
• Lower only if the applicant can secure safe-harbor design around later claims (usually method-of-use or certain formulation elements) and still demonstrate acceptable potency and safety.

---

Which companies lead the antisense oligonucleotide market and what IP positioning do they use?

The ASO landscape is split between:

1. Integrated platform owners with proprietary chemistries and delivery approaches,
2. Target-specific sequence developers with strong method-of-use and clinical regimen claims,
3. Licensing partners that control manufacturing know-how and regulatory ownership.

Typical IP positioning strategies

• Platformization: claim the chemistry space and delivery paradigms across multiple targets. This expands enforcement beyond one product.
• Indication stacking: maintain patent value by filing new method-of-use and combination regimens as clinical programs broaden beyond initial indication.
• Conjugation/delivery ownership: secure exclusivity around delivery improvements that differentiate subsequent products and line extensions.

---

What manufacturing and formulation patents can block antisense oligonucleotide competitors?

Even if sequence and method-of-use claims are designed around, manufacturing patents can remain a bottleneck.

Common manufacturing patent hooks in ASOs

• Defined synthetic intermediates and coupling conditions.
• Specific purification sequences and acceptance criteria (impurity profiling).
• Analytical methods to confirm structure and measure truncation products.
• Scale-up and batch reproducibility methods linked to stability outcomes.

What about formulation patent barriers?

• Many ASO products are sensitive to aggregation and require tight control over buffers and excipients.
• Patents often claim:
  • specific concentrations and tonicity agents,
  • pH and buffer systems,
  • storage conditions and stability data,
  • particle or aggregate limits.

---

Which biosimilar-like risks exist for antisense oligonucleotides?

ASOs are not biologics in the biosimilar sense, so the “biosimilar pathway” is not the direct analogue. The practical biosimilar risk pattern still matters:

• Structural similarity does not guarantee functional identity.
• Small manufacturing process changes can shift impurities and pharmacokinetics.
• Tissue distribution effects can create clinically meaningful differences.

For investors and litigators, the key implication is that “follow-on” ASO developers face both regulatory burden and IP risk, with fewer safe harbors than in small molecules.

---

What patent litigation affects antisense oligonucleotide competition?

ASO litigation typically centers on:

• Validity of sequence/chemistry claims,
• Infringement by accused sequence variants,
• Indefiniteness and written description challenges tied to structural claim scope,
• Obviousness arguments that combine prior art chemistries, assays, and target disclosures.

Litigation timing pressures

ASO assets often have:

• Shorter commercial plateaus in orphan indications once exclusivity expires,
• Pressure to settle before launch windows.

Litigation also affects:

• How quickly an accused product can be manufactured under a non-infringing supply plan,
• Whether a design-around is feasible at scale.

---

What generic entry risks exist for antisense oligonucleotide drugs?

High-risk scenarios

• Applicant launches with highly similar sequence and chemistry.
• Applicant relies on “functionally equivalent” arguments that do not map cleanly to claim language.
• Applicant cannot demonstrate a non-infringing manufacturing route.

Lower-risk scenarios

• Applicant targets method-of-use carve-outs that avoid labeled regimens (and secures non-infringement clearance).
• Applicant uses materially different chemistry that avoids structural claims while maintaining potency.
• Applicant resolves manufacturing and impurity control pathways early enough to avoid being blocked by process patents.

In practice, entry risk depends on whether the remaining listed patents are sequence/chemistry or method-of-use/formulation.

---

Timeline view: how exclusivity and patent expiry shape ASO launch windows

Because ASOs often have multiple overlapping patent families, market timing is best represented as a corridor rather than a single date.

Typical sequence of constraints

1. NDA approval date and marketing exclusivity clock (if applicable).
2. Patent expiry schedule from Orange Book listing: earliest date and final “last-to-expire” patent.
3. Potential Paragraph IV filing window: tied to statutory frameworks and eligibility to seek early submission.
4. Litigation and settlement terms that set a negotiated launch date.
5. Post-launch: continued enforcement against additional variants or delivery improvements.

---

Key Takeaways

• ASO patent estates are layered across sequence, chemical modification, delivery/formulation, method-of-use, and manufacturing, making “generic ASO” entry structurally harder than small-molecule generics.
• Exclusivity timelines can be less decisive than patent-by-patent expiry schedules because later-expiring formulation, regimen, and process patents commonly preserve leverage.
• Orange Book status is critical for assessing which patents remain enforceable and which category (drug substance, drug product, methods of use) controls real entry risk.
• Litigation and settlement dynamics in ASOs hinge on whether applicants can design around sequence/chemistry versus only carving out method-of-use or delivery elements.
• Competitiveness depends on both IP strategy (platformization, indication stacking, delivery ownership) and manufacturing defensibility (impurity control and reproducible synthesis).

---

FAQs

1) Do antisense oligonucleotides qualify for ANDA-style “generic” approval like small molecules?
Regulatory treatment emphasizes complex identity and functional equivalence, so “generic ASO” concepts face higher technical and IP constraints than small-molecule ANDAs.

2) What patent categories usually block an ASO competitor even after exclusivity expires?
Drug substance and methods of use tend to be the most blocking, but formulation and manufacturing patents can also stop supply or market entry.

3) Can an ASO follow-on avoid infringement by targeting a different dosing regimen?
It can reduce risk if method-of-use claims are dominant, but it does not solve sequence/chemistry infringement where drug-substance claims remain active.

4) Why are manufacturing and impurity-control patents significant in ASO litigation?
Because process changes can alter truncation/impurity profiles that map to claimed manufacturing routes and support infringement arguments.

5) Are there biosimilar-like “data equivalence” strategies for ASO follow-ons?
Not in the formal biosimilar sense, but sponsors often rely on structural and functional characterization expectations that make “bridge” evidence more burdensome than for small molecules.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. FDA. Guidance for Industry: Regulatory Considerations for Complex Products (general principles for complexity and comparability). https://www.fda.gov/regulatory-information/search-fda-guidance-documents
3. U.S. Code. 35 U.S.C. § 271, Hatch-Waxman framework (Paragraph IV concept via 21 U.S.C. § 355). https://uscode.house.gov/
4. FDA. Orphan Drug Designation and Exclusivity information (general orphan exclusivity rules). https://www.fda.gov/industry/designating-orphan-product-drug-or-biological-product/